Janux stock plunges after hours following mCRPC trial data
Investing.com - RBC Capital upgraded Design Therapeutics Inc (NASDAQ:DSGN) from Sector Perform to Outperform and more than doubled its price target to $13.00 from $6.00. The new target represents significant upside from DSGN’s current price of $7.34, which has already surged 100% over the past six months according to InvestingPro data.
The upgrade comes as RBC analyst Leonid Timashev anticipates a "more eventful 2026" for the company, with particular focus on the new DT-216p2 formulation for Design’s lead Friedreich’s ataxia (FA) program.
RBC believes the drug can demonstrate "clinically meaningful benefits and drive a significant stock inflection" based on analysis of how the P2 formulation affects mRNA and protein expression.
The firm suggests positive clinical data could renew interest in Design’s platform technology, with additional upside potential from the company’s DT-168 Fuchs program and its DM1 (myotonic dystrophy type 1) program.
RBC projects Design Therapeutics could generate more than $1.9 billion in revenues by 2034, maintaining that the company "is not receiving sufficient credit" for its pipeline potential while keeping its Speculative Risk qualifier unchanged.
In other recent news, Design Therapeutics announced it has received regulatory clearance outside the United States for DT-818, a small molecule developed for the treatment of myotonic dystrophy type-1. The company plans to initiate a Phase 1 trial in Australia, focusing on multiple-ascending doses, during the first half of 2026. This trial aims to gather splicing data, with results anticipated in 2027. These developments mark a significant step forward in the company’s research efforts. Design Therapeutics continues to advance its pipeline in the clinical-stage biotechnology sector. The clearance allows the company to extend its research capabilities beyond the U.S. as it explores potential treatments for myotonic dystrophy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.